Protocol Ledger

NCT06820957 · Phase II/III · TERMINATED

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Interventional Phase II/III clinical trial protocol NCT06820957 sponsored by Children's Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-10 Enrollment: 2 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06820957
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06820957
Protocol FieldVerified Registry Value
NCT IdentifierNCT06820957
Consolidated Lead SponsorChildren's Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment2 participants (ACTUAL)
Registered Start Date2025-11-10
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06820957
Hospital Research SiteLocationSite Profile
Children's Hospital of AlabamaBirmingham, ALOpen Hospital Dossier ->
Kapiolani Medical Center for Women and ChildrenHonolulu, HIOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI